Vergote I, et al. - In TRINOVA-3 (a multicenter, multinational, phase 3, double-blind study), researchers focused on the efficacy of trebananib (a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2) added to carboplatin and paclitaxel for improving progression-free survival when given as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer. The treatment regimen for eligible patients involved administration of six cycles of paclitaxel (175 mg/m²) and carboplatin (area under the serum concentration-time curve 5 or 6) every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo, using a permuted block method (block size of six patients). For up to 18 additional months, trebananib or placebo were continued as maintenance therapy. In advanced ovarian cancer, no improvement in progression-free survival was achieved with trebananib plus carboplatin and paclitaxel as first-line therapy. No new safety issues were reported, and minimal effectiveness was offered by the combination of trebananib plus carboplatin and paclitaxel.